Impact of pre-existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study

Anna Jansana; Aviane Auguste; Marina Kvaskoff; Agnès Fournier; Emma Fontvieille; Laia Peruchet-Noray; Carine Biessy; Reynalda Cordova; Kristina Elin Nielsen Petersen; Anne Tjønneland; Verena Katzke; Rudolf Kaaks; Fulvio Ricceri; Salvatore Panico; Paolo Contiero; Maria-Jose Sánchez; Jesus Castilla; Marta Crous-Bou; Alicia Heath; Elom Kouassivi Aglago; Elisabete Weiderpass; Marc James Gunter; Pietro Ferrari; Elio Riboli; Vivian Viallon; Heinz Freisling

doi:10.1002/cac2.12526

Cancer Communications ›› 2024, Vol. 44 ›› Issue (5) :593 -597. DOI: 10.1002/cac2.12526

LETTER TO THE JOURNAL

Impact of pre-existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study

Author information +

¹. International Agency for Research on Cancer (IARC-WHO), Lyon, France

². Paris-Saclay University, University of Versailles-Saint-Quentin-en-Yveline, University Paris-Sud, French National Institute for Health and Medical Research (Inserm), Gustave Roussy, “Exposome and Heredity” Team, CESP, Villejuif, France

³. Department of Nutritional Sciences, University of Vienna, Vienna, Austria

⁴. Danish Cancer Society Research Center, Copenhagen, Denmark

⁵. Department of Public Health, University of Copenhagen, Copenhagen, Denmark

⁶. Division of Cancer Epidemiology, German Cancer Research Centre, Heidelberg, Germany

⁷. Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

⁸. Unit of Epidemiology, Regional Health Service ASL TO3, Grugliasco, Turin, Italy

⁹. Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

¹⁰. Environmental Epidemiology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS)-Istituto Nazionale dei Tumori, Milan, Italy

¹¹. Cancer Registry of Granada, Institute for Biosanitary Research of Granada (ibs.GRANADA), Granada, Spain

¹². Epidemiology and Control of Chronic Diseases Group, Epidemiology and Public Health Networking Biomedical Research Centre, Madrid, Spain

¹³. Navarra Public Health Institute, Pamplona, Spain

¹⁴. Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO)-Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain

¹⁵. Department of Epidemiology, Harvard Tseng-Hsi Chan School of Public Health, Boston, Massachusetts, USA

¹⁶. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, UK

freislingh@iarc.who.int

Show less

History +

PDF

Cite this article

Download citation ▾

Anna Jansana, Aviane Auguste, Marina Kvaskoff, Agnès Fournier, Emma Fontvieille, Laia Peruchet-Noray, Carine Biessy, Reynalda Cordova, Kristina Elin Nielsen Petersen, Anne Tjønneland, Verena Katzke, Rudolf Kaaks, Fulvio Ricceri, Salvatore Panico, Paolo Contiero, Maria-Jose Sánchez, Jesus Castilla, Marta Crous-Bou, Alicia Heath, Elom Kouassivi Aglago, Elisabete Weiderpass, Marc James Gunter, Pietro Ferrari, Elio Riboli, Vivian Viallon, Heinz Freisling. Impact of pre-existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study. Cancer Communications, 2024, 44(5): 593-597 DOI:10.1002/cac2.12526

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Renzi C, Kaushal A, Emery J, Hamilton W, Neal RD, Rachet B, et al. Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms. Nat Rev Clin Oncol. 2019;16(12):746–61.

[2]	Sattar N, Gill JMR, Alazawi W. Improving prevention strategies for cardiometabolic disease. Nat Med. 2020;26(3):320–5.

[3]	Zaborowski AM, Abdile A, Adamina M, Aigner F, d'Allens L, Allmer C, et al. Characteristics of Early-Onset vs Late-Onset Colorectal Cancer: A Review. JAMA Surg. 2021;156(9):865–74.

[4]	Mobley LR, Tangka FKL, Berkowitz Z, Miller J, Hall IJ, Wu M, Sabatino SA. Geographic Disparities in Late-Stage Breast Cancer Diagnosis Rates and Their Persistence Over Time. J Womens Health (Larchmt). 2021;30(6):807–15.

[5]	Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016;66(4):337–50.

[6]	Gabler M, Geier S, Mayerhoff L, Rathmann W. Cardiovascular disease prevalence in type 2 diabetes - an analysis of a large German statutory health insurance database. BMC Public Health. 2021;21(1):328.

[7]	Boakye D, Günther K, Niedermaier T, Haug U, Ahrens W, Nagrani R. Associations between comorbidities and advanced stage diagnosis of lung, breast, colorectal, and prostate cancer: A systematic review and meta-analysis. Cancer Epidemiol. 2021;75:102054.

[8]	Qiang JK, Sutradhar R, Giannakeas V, Bhatia D, Singh S, Lipscombe LL. Impact of diabetes on colorectal cancer stage and mortality risk: a population-based cohort study. Diabetologia. 2020;63(5):944–53.

[9]	von Wagner C, Cadar D, Hackett RA, Demakakos P, Beeken RJ, Cooper Bailey S, et al. Type 2 diabetes and colorectal cancer screening: Findings from the English Longitudinal Study of Ageing. J Med Screen. 2020;27(1):25–30.

[10]	Li P, Hu Y, Scelo G, Myrskylä M, Martikainen P. Pre-existing psychological disorders, diabetes, and pancreatic cancer: A population-based study of 38,952 Finns. Cancer Epidemiol. 2023;82:102307.